Hormone Health & Wellness of Colorado
Grand Junction, Colorado · (970) 812-5115
Listed on the clinic's site as: CJC-1295 / Ipamorelin, Sermorelin/Ipamorelin
This directory has 5 source-reviewed clinics in 5 cities across 5 states that name CJC-1295 and ipamorelin on their own websites. Each clinic below names CJC-1295 or ipamorelin on its own website. Some name only one of the two, as shown on each listing.
Service lists checked October 28, 2026. Counts exclude imported records that have not been source-reviewed. How we verify.
Colorado (1)Georgia (1)North Carolina (1)Utah (1)Washington (1)
Alpharetta, Georgia (1)Bothell, Washington (1)Charlotte, North Carolina (1)Grand Junction, Colorado (1)Sandy, Utah (1)
5 of the 50 reviewed clinics name CJC-1295 and ipamorelin (10%). Largest states: Colorado (1), Georgia (1), North Carolina (1), Utah (1). 5 of 5 records carry a phone number.
Clinics on this page that also name: 5 Sermorelin; 4 BPC-157; 2 Tesamorelin.
None of these records carries a sourced numeric price.
Service lists checked October 28, 2026.
Grand Junction, Colorado · (970) 812-5115
Listed on the clinic's site as: CJC-1295 / Ipamorelin, Sermorelin/Ipamorelin
Alpharetta, Georgia · 678-361-6615
Listed on the clinic's site as: CJC1295 + Ipamorelin
Charlotte, North Carolina · (704) 360-5018
Listed on the clinic's site as: CJC-1295, Ipamorelin
Sandy, Utah · 385-240-1000
Listed on the clinic's site as: CJC-1295, Ipamorelin
Bothell, Washington · (425) 485-1413
Listed on the clinic's site as: Ipamorelin
Questions to ask a clinic before you book are on the peptide therapy page and in how to verify a peptide clinic.
5 source-reviewed clinics in 5 cities and 5 states name CJC-1295 and ipamorelin in the services on their own websites. Imported records that have not been source-reviewed are not counted.
The page says the FDA has identified serious adverse events associated with CJC-1295, including increased heart rate, and lists it among substances nominated but withdrawn. It also places ipamorelin acetate in category 2 under the 503B interim policy. The page said it was current as of 04/22/2026.
Source: FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, checked November 9, 2026.
Opened and checked October 28, 2026 unless a source shows its own date. These are the regulator's own pages. They describe what the regulator says, not what any listed provider offers.
Counts by state and service: Peptide clinics by state (data).